PRESS RELEASE published on 05/16/2025 at 17:45, 1 year 3 months ago Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital Median Technologies discloses total voting rights and shares as of April 30, 2025, in compliance with regulations. The French company utilizes AI for cancer diagnosis and treatment Voting Rights Shares AI Median Technologies Cancer Diagnosis
PRESS RELEASE published on 05/16/2025 at 17:45, 1 year 3 months ago Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital Déclaration du nombre total de droits de vote et du nombre d’actions composant le capital de Median Technologies au 30 avril 2025, société spécialisée en logiciels dispositifs médicaux et imagerie médicale Déclaration Droits De Vote Actions Median Technologies Logiciels Médicaux
BRIEF published on 03/14/2025 at 17:50, 1 year 5 months ago Median Technologies Maintient son Éligibilité au Dispositif PEA-PME PEA-PME Euronext Growth Éligibilité Avantages Fiscaux Median Technologies
BRIEF published on 03/14/2025 at 17:50, 1 year 5 months ago Median Technologies Maintains its Eligibility for the PEA-PME Scheme PEA-PME Euronext Growth Tax Benefits Eligibility Median Technologies
PRESS RELEASE published on 03/14/2025 at 17:45, 1 year 5 months ago Etat membre d'origine / Choix de l’autorité compétente pour le contrôle de l’information réglementée Median Technologies confirms eligibility for the PEA-PME scheme, meeting criteria of <5,000 employees and annual turnover <1.5 billion euros. Shares remain in PEA-PME accounts with tax benefits Eligibility Criteria Tax Advantages Median Technologies PEA-PME Scheme Stock Savings Plan
BRIEF published on 02/24/2025 at 17:50, 1 year 6 months ago Median Technologies : Présentation d'eyonis™ LCS à l'ECR 2025 Intelligence Artificielle Median Technologies Cancer Du Poumon Eyonis™ LCS ECR 2025
BRIEF published on 02/24/2025 at 17:50, 1 year 6 months ago Median Technologies: Presentation of eyonis™ LCS at ECR 2025 Artificial Intelligence Median Technologies Lung Cancer Eyonis™ LCS ECR 2025
PRESS RELEASE published on 02/24/2025 at 17:45, 1 year 6 months ago Informations privilégiées / Autres communiqués Median Technologies présentera eyonis™ LCS, logiciel IA pour dépistage cancer poumon, à l’ECR. Validation clinique réussie. Dossiers réglementaires soumis bientôt IA Dépistage Median Technologies Cancer Du Poumon Eyonis LCS
BRIEF published on 01/31/2025 at 08:05, 1 year 7 months ago Median Technologies dévoile ses résultats financiers 2024 et ses perspectives 2025 Résultats Financiers Median Technologies Eyonis™ LCS FDA Approbation Expansion 2025
BRIEF published on 01/31/2025 at 08:05, 1 year 7 months ago Median Technologies unveils its 2024 financial results and its 2025 outlook Financial Results FDA Approval Median Technologies Eyonis™ LCS Expansion 2025
Published on 09/12/2026 at 02:35, 1 day 5 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 1 day 9 hours ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 21:25, 1 day 10 hours ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day 15 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 14 hours 25 minutes ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 1 day ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 1 day 10 hours ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 day 10 hours ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 1 day 12 hours ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 2 days 1 hour ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 2 days 1 hour ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 2 days 12 hours ago Availability of the 2026 Interim Financial Report